- Conditions
- Infection, Candida, Non Albicans Species
- Interventions
- Not listed
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- Not listed
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2017
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 628
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Influenza A Subtype H5N1 Infection
- Interventions
- Pandemic Influenza Vaccine, Placebo
- Biological
- Lead sponsor
- Altimmune, Inc.
- Industry
- Eligibility
- 19 Years to 49 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- HIV Infections, Hyperlipidemia
- Interventions
- oyster mushroom
- Drug
- Lead sponsor
- National Center for Complementary and Integrative Health (NCCIH)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- HIV Infections
- Interventions
- Vitamin D supplement, Placebo
- Dietary Supplement · Other
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 24 Years
- Enrollment
- 207 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 14
- States / cities
- Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 10 more
- Conditions
- HIV, AIDS
- Interventions
- Kaletra (drug)
- Drug
- Lead sponsor
- Lampiris, Harry W., M.D.
- Individual
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- HIV Infections
- Interventions
- DTG 50 mg, RPV 25 mg, CAR
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 13
- States / cities
- Long Beach, California • Los Angeles, California • San Francisco, California + 9 more
- Conditions
- Systemic Inflammatory Response Syndrome (SIRS), Sepsis, Severe Sepsis, Septic Shock
- Interventions
- Not listed
- Lead sponsor
- Axis Shield Diagnostics Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 759 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Camden, New Jersey
- Conditions
- Diabetic Foot Infection, Non-healing Wound, Non-healing Diabetic Foot Ulcer
- Interventions
- TTAX01, Standard care
- Biological · Other
- Lead sponsor
- BioTissue Holdings, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 106 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 16
- States / cities
- Guntersville, Alabama • Tucson, Arizona • Los Angeles, California + 12 more
- Conditions
- AIDS-related Non-Hodgkin Lymphoma, AIDS-related Plasmablastic Lymphoma, AIDS-related Primary Effusion Lymphoma, HIV Infection
- Interventions
- busulfan, lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells, pharmacological study, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2027
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection, Chronic Granulomatous Disease, HIGM-1, Leukocyte Adhesion Deficiency, IPEX
- Interventions
- Hematopoietic Stem Cell Transplant
- Biological
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 4 Months to 45 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Atlanta, Georgia + 16 more
- Conditions
- Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Epstein-Barr Virus Infection, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Adult Hodgkin Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
- Interventions
- brentuximab vedotin, rituximab, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 3
- States / cities
- Chicago, Illinois • Boston, Massachusetts
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Interventions
- Placebo, LX211
- Drug
- Lead sponsor
- Lux Biosciences, Inc.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 218 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 16 more
- Conditions
- Meningitis, Cryptococcal, HIV Infections
- Interventions
- Fluconazole
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 4
- States / cities
- Chicago, Illinois • Newark, New Jersey • Brooklyn, New York + 1 more
- Conditions
- Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
- Interventions
- Placebo, LX211
- Drug
- Lead sponsor
- Lux Biosciences, Inc.
- Industry
- Eligibility
- 13 Years and older
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 16 more
- Conditions
- Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma (NHL), Hodgkin's Lymphoma
- Interventions
- Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative), Fludarabine, Melphalan, ATG (Reduced Intensity)
- Drug
- Lead sponsor
- Targazyme, Inc.
- Industry
- Eligibility
- 1 Year to 80 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 4
- States / cities
- La Jolla, California • Cleveland, Ohio • Houston, Texas + 1 more
- Conditions
- HIV Infections
- Interventions
- Emivirine, Nelfinavir mesylate
- Drug
- Lead sponsor
- Triangle Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- HIV Infections
- Interventions
- Cell Transfer
- Drug
- Lead sponsor
- National Institutes of Health Clinical Center (CC)
- NIH
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- HIV Infections
- Interventions
- Amprenavir
- Drug
- Lead sponsor
- Glaxo Wellcome
- Industry
- Eligibility
- 13 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
- Conditions
- HIV Infections
- Interventions
- Efavirenz, Emtricitabine, Stavudine, Didanosine
- Drug
- Lead sponsor
- Triangle Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 51
- States / cities
- Birmingham, Alabama • Berkeley, California • Concord, California + 38 more
- Conditions
- Gonorrhea, Chlamydia, Syphilis
- Interventions
- On demand doxycycline hyclate 200mg, Daily doxycycline hyclate 100mg, Weekly doxycycline hyclate 100mg
- Drug
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Alcohol Dependence, HIV/AIDS
- Interventions
- Clinician Guide (CG), Clinician Guide plus HealthCall
- Behavioral
- Lead sponsor
- Research Foundation for Mental Hygiene, Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Hodgkin Disease, Non Hodgkin Lymphoma, Lymphoepithelioma, Severe Chronic Active EBV Infection Syndrome (SCAEBV), Leiomyosarcoma
- Interventions
- LMP1/2 CTLs (Group A), LMP1/2 CTLs (Group B)
- Drug
- Lead sponsor
- Catherine Bollard
- Other
- Eligibility
- Not listed
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Non-infectious Uveitis
- Interventions
- EYS606
- Combination Product
- Lead sponsor
- Eyevensys
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 3
- States / cities
- Cleveland, Ohio • Arlington, Texas • Houston, Texas
- Conditions
- Hypertension, Diabetes Mellitus, Type 2
- Interventions
- Not listed
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts